10
Participants
Start Date
January 25, 2021
Primary Completion Date
June 1, 2022
Study Completion Date
October 30, 2022
Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib
"Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name:M1-c6v1~Drug:Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names:SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib"
Collaborators (1)
Guangzhou Virotech Pharmaceutical Co., Ltd.
INDUSTRY
Liang Peng
OTHER